Products
Reozalimab Biosimilar Bispecific Antibody (PD-1 × PD-L1) for Research
Cat No.: GMP-Bios-INN-1364
Anti-PDCD1/CD279/PD1 therapeutic antibody (Pre-made Reozalimab biosimilar,Bispecific mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Reozalimab (development codes LY-3434172/LY 343172) is a bispecific monoclonal antibody targeting PD-1 (PDCD1) and PD-L1 (CD274). It is developed by Innovent Biologics for Solid tumours in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1364-1mg | 1mg | |
| GMP-Bios-INN-1364-10mg | 10mg | |
| GMP-Bios-INN-1364-100mg | 100mg | |
| GMP-Bios-INN-1364-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Reozalimab biosimilar, Bispecific mAb, Anti-PDCD1/CD279/PD1;PDL1/CD274 Antibody: Anti-PD-1/CD279/PDCD1/Programmed cell death protein 1 therapeutic antibody |
| INN Name | Reozalimab |
| Target | PDCD1/CD279/PD1;PDL1/CD274 |
| Format | Bispecific mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Innovent Biologics |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
